Navigation Links
Link between obesity and enhanced cancer risk elucidated
Date:1/21/2010

Epidemiological studies indicate that being overweight or obese is associated with increased cancer risk. The most dramatic effect of obesity on cancer risk has been noted for a common form of liver cancer called hepatocellular carcinoma or HCC. Modeling the effect of obesity in mice, researchers at the University of California, San Diego School of Medicine have conclusively demonstrated that obesity is tumor-promoting and have obtained evidence that this effect depends on induction of low-grade, chronic inflammation.

Their results, published January 22 by the journal Cell, may suggest novel therapy to prevent HCC development in obese men who suffer from chronic liver disease.

Michael Karin, PhD, Distinguished Professor of Pharmacology in UCSD's Laboratory of Gene Regulation and Signal Transduction, who led the study, found that obesity enhanced the development of HCC by stimulating the production of tumor-promoting cytokines interleukin-6 (Il-6) and tumor necrosis factor (TNF) that also cause chronic inflammation. Production of these signaling molecules, which are elevated in obese mice and in humans, causes inflammation of the liver and activation of a tumor-promoting transcription factor, a protein called STAT3. This protein in turn activates the formation and growth of liver cancer.

The primary role of TNF is in the regulation of immune cells, but its deregulated production can cause diseases such as rheumatoid arthritis or Crohn's disease. Ironically, while TNF was also tested for its ability to kill cancer, its chronic production was found to actually enhance tumor development.

IL-6 is known to be involved in the pathogenesis of rheumatoid arthritis, but previous work in the Karin lab has shown that IL-6 also contributes to the chronic inflammation that leads to liver cancer. HCC a devastating complication of chronic liver disease and inflammation caused by risk factors such as hepatitis B and C viruses, or alcoholic liver disease makes up the majority of liver cancers in humans and is the third-leading cause of death worldwide. Recent epidemiological studies have confirmed the critical role of IL-6 in the progression of viral hepatitis to HCC in humans. However, the mechanisms by which obesity strongly increased the risk of HCC had remained a mystery.

"The chronic inflammatory response caused by obesity and enhanced production of circulating IL-6 and TNF may also increase the risk of other cancers," Karin added.

The actual increase in cancer risk is dependent on the type of cancer and the body-mass-index (BMI). The largest effect of BMI higher than 25 (the recommended BMI level) is seen on HCC; the risk of this type of liver cancer is increased by up to 4.5-fold in men with a BMI of between 35 and 40. But the effect of excess body weight increases the risk of all cancers 1.5-fold in men and 1.6-fold in women, according to Karin.

"In addition to HCC, obesity markedly increases the risk of pancreatic, gastrointestinal tract and kidney cancers," he said. "Given the prevalence of obesity in the Western and developing worlds, even a modest increase in cancer risk represents a major public health problem."

The new UCSD research suggests that anti-TNF drugs, currently used in the treatment of chronic inflammatory diseases, may be used to prevent HCC development in obese men who suffer from chronic liver disease. According to the studies in mice, inhibition of TNF signaling may even prevent hepatosteatosis, or accumulation of fat in the liver.


'/>"/>

Contact: Debra Kain
ddkain@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

Related medicine news :

1. Comparison of obstetric outcomes between on-call and patients own obstetricians
2. Mailman School of Public Health study examines link between racial discrimination and substance use
3. New link between estrogen and breast cancer
4. Link Uncovered Between Benign Prostatic Hyperplasia and NSAIDs, Says Harvard Mens Health Watch
5. Link Between Chronic Pain and Insomnia Uncovered at PAINWeek 2007
6. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds
7. Researchers discover correlation between GERD and obesity in females
8. NIH awards $10.8M to Columbia to study connection between diabetes and heart disease
9. Researchers Pinpoint Link Between Caloric Restriction and Longevity
10. Link Between Air Pollution, Stroke Gets Clearer
11. No Link Between Anti-Nausea Drug, Heart Trouble
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... ... services to provide one resource, from start to finish, for Life Safety compliance. ... Statement of Condition surveys requested by the Joint Commission, and fire stopping reviews, ...
(Date:5/24/2016)... ... May 24, 2016 , ... Jericho Project has named LaToya Williams-Belfort to ... be responsible for fundraising and communications for the nationally-acclaimed nonprofit, working closely with CEO ... working to end homelessness at its roots. , “LaToya Williams-Belfort is joining Jericho ...
(Date:5/24/2016)... ... May 24, 2016 , ... Educational opportunities, and ... with more advantaged communities providing richer opportunities. Recognizing the key role of housing ... improvement policies; (b) school choice policies; (c) school desegregation policies; (d) wealth-focused policies; ...
(Date:5/24/2016)... ... May 24, 2016 , ... New Brunswick, New Jersey: This year marks ... reach their fullest potential. To commemorate the anniversary, the hospital has themed the milestone ... Roll for Children’s Specialized Hospital Foundation on Saturday, May 21, at Johnson Park in ...
(Date:5/24/2016)... ... (PRWEB) May 24, ... new members of its Advisory Board. Joining the Grow Healthy ... “All three of them embody the mission of our organization and ... fortunate to have them as we continue to expand our footprint ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... May 24, 2016 Celsion Corporation (NASDAQ: ... company, today provided an update on its ongoing ... trial combining GEN-1, the Company,s DNA-based immunotherapy, with ... newly-diagnosed patients with advanced ovarian cancer who will ... GEN-1 is an IL-12 DNA plasmid vector formulated ...
(Date:5/24/2016)... 24, 2016 The innovator ... , s first dual therapy stent, introduces ... OrbusNeich, a global company specializing in the ... to include products to treat peripheral artery disease. The ... entry devices for lower limb and arteriovenous (AV) fistula ...
(Date:5/24/2016)... 24, 2016 ... , la première endoprothèse à double thérapie ... l,intervention portant sur les membres inférieurs et ... OrbusNeich, entreprise mondiale spécialisée dans la fourniture ... vie, a élargi son portefeuille pour inclure ...
Breaking Medicine Technology: